Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rapid Micro Biosystems, Inc. (NASDAQ: RPID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an emerging growth company listed on Nasdaq, Rapid Micro Biosystems reports material events, financial results, and financing arrangements through forms such as Form 8-K, as well as its periodic reports on Forms 10-Q and 10-K.
Recent 8-K filings referenced in company communications include results of operations and financial condition for specific quarters and details of a Loan and Security Agreement with Trinity Capital Inc. These filings describe a five-year, $45 million term loan facility, the structure of tranches, interest terms, security interests in company assets, warrant issuance to lenders, and customary covenants and events of default. Other 8-K items incorporate press releases announcing quarterly financial results, including product revenue, service revenue, recurring revenue, and system placement and validation activity.
Through this page, users can review quarterly reports (Form 10-Q), which typically contain more detailed financial statements, segment information, and risk factor updates, and annual reports (Form 10-K), which provide a comprehensive overview of the company’s business, including its Growth Direct system, microbial quality control focus, and role in pharmaceutical manufacturing quality control. Filings related to debt facilities, warrant issuance, and other securities transactions are also accessible.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as revenue composition, recurring revenue trends, capital structure changes, covenant terms, and material events. Users interested in Rapid Micro Biosystems’ regulatory history, financial condition, and obligations under its loan facility can use this page to follow new filings as they are made available through EDGAR.
Robert G. Spignesi filed a Form 144 notifying a proposed sale of 17,922 Class A shares arising from restricted stock vesting on 03/09/2026.
The notice also reports prior sales of 12,840 Class A shares on 02/09/2026 for $48,569.87 and 38,327 Class A shares on 02/19/2026 for $148,911.89. Shares outstanding were reported as 39,823,026 as of 03/10/2026.
RAPID MICRO BIOSYSTEMS, INC. director Natale S. Ricciardi exercised a stock option and acquired Class A common shares. On February 27, 2026, he exercised an option for 842 shares at an exercise price of $0.75 per share. Following the exercise, his direct holdings of Class A common stock increased to 29,442 shares. The footnote indicates the option was already fully vested and exercisable, meaning this transaction reflects the use of an existing equity award rather than a new grant or open-market purchase.
RAPID MICRO BIOSYSTEMS, INC. chief operating officer John J. Wilson reported an automatic sale of 5,403 shares of Class A common stock at $3.923 per share. According to the footnote, this sale was made solely to cover tax obligations tied to vesting restricted stock units. After the transaction, he directly held 326,365 shares of Class A common stock.
RAPID MICRO BIOSYSTEMS, INC. Chief Financial Officer Sean M. Wirtjes reported an automatic sale of Class A common stock to cover taxes tied to restricted stock unit vesting. He sold 17,254 shares at an average price of $3.923 per share. After this tax-related sale, he continues to hold 563,674 shares directly.
RAPID MICRO BIOSYSTEMS, INC. president and CEO Robert G. Spignesi Jr. reported a sale of 38,327 shares of Class A common stock on February 19, 2026 at an average price of $3.8853 per share. A footnote explains this was an automatic sale to cover tax obligations arising from the vesting of restricted stock units, rather than a discretionary open-market trade. After this transaction, he still holds 1,187,770 shares of the company’s Class A common stock directly.
RPID reported a proposed sale of 5,403 shares of Class A common stock under Rule 144.
The notice shows the shares are associated with a Restricted Stock Vesting event dated 02/19/2026, and it discloses a prior sale of 4,610 shares on 02/09/2026.
Sean M. Wirtjes reports a proposed sale of Class A shares. The notice lists 17,254 Class A shares to be sold in connection with restricted stock vesting dated 02/19/2026. The filing also reports 6,027 Class A shares sold on 02/09/2026.
RPID filed a Form 144 reporting a proposed sale of Class A shares by an affiliate. The filing lists 38,327 Class A shares to be sold with an aggregate amount of $148,911.89, dated 02/18/2026. The filing also shows 12,840 Class A shares sold during the past three months for $48,569.87.
Rapid Micro Biosystems chief operating officer John J. Addington Wilson received new equity awards as part of his compensation. He was granted 74,000 shares of Class A common stock, reported at a price of $0 and bringing his direct holdings to 331,768 shares. These shares represent restricted stock units that vest over three years, with 33.4% vesting on the first anniversary of February 11, 2026 and 33.3% on each of the next two anniversaries, conditioned on continued service. He was also granted a stock option for 147,000 shares of Class A common stock with a $4.20 exercise price, expiring on February 10, 2036. The option vests in 48 equal monthly installments starting March 11, 2026, leaving him with 147,000 options beneficially owned after the transaction.
Rapid Micro Biosystems, Inc. reported an equity compensation grant to its Chief Financial Officer, Sean M. Wirtjes. On February 11, 2026, he received 97,000 Class A common stock restricted stock units, awarded at $0 per share, increasing his directly held Class A shares to 580,928 after the grant.
He was also granted a stock option for 193,000 shares of Class A common stock with an exercise price of $4.2 per share. The RSUs vest in three annual installments starting on the first anniversary of the grant date, while the option vests in 48 equal monthly installments beginning March 11, 2026, contingent on continued service.